PHARMASIMPLE
A bankruptcy procedure is open for PHARMASIMPLE according to publications in the Belgian State Gazette. The 2021 annual accounts show equity of €4.14M and a net result of €-8.94M.
| Equity | €4.14M |
| Net result | €-8.94M |
| Staff (FTE) | 57.9 |
| Better than sector | 47% |
Fragile profile, watch health in particular.
All 5 axes are computed from data Checked has read.
Bankruptcy opened
A bankruptcy procedure is already open, a probability score is no longer meaningful. See the insolvency timeline for the state of the procedure.
Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 22.8% | 25.2% | |
| Net result | €-8.94M | €17k | |
| Equity | €4.14M | €133k | |
| Staff costs | €3.35M | €151k | |
| Employees (FTE) | 57.9 | 5.5 |
| Fiscal year | 2021 |
|---|---|
| Deposit | volledig |
| Revenue | €29.90M |
| EBITDA | €-7.64M |
| Net profit | €-8.94M |
| Cash flow | €-8.02M |
| Staff costs | €3.35M |
| Income taxes | €1k |
| Dividends | - |
| Total assets | €18.19M |
| Equity | €4.14M |
| Debt | €14.05M |
| of which ≤ 1y | €8.49M |
| of which > 1y | €5.52M |
| Working capital | €1.10M |
| Employees (FTE) | 57.9 |
| 2021 | |
|---|---|
| Current ratio | 1.13 |
| Quick ratio | 0.76 |
| Working capital ratio | 6.1% |
| Solvency | 22.8% |
| Debt / equity | 3.39 |
| Long-term debt ratio | 1.33 |
| Interest coverage | -22.52 |
| Gross margin | 11.0% |
| Net margin | -29.9% |
| ROA | -49.1% |
| ROE | -215.6% |
| EBITDA margin | -25.6% |
| Days sales outstanding | 56d |
| Days payable outstanding | 54d |
| Inventory turnover | 8.46 |
| Days inventory (DSI) | 43d |
| Line item | Code | 2021 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €18.19M |
| Fixed assets | 21/28 | €8.44M |
| Formation expenses | 20 | €161k |
| Intangible fixed assets | 21 | €1.05M |
| Tangible fixed assets | 22/27 | €268k |
| Financial fixed assets | 28 | €7.13M |
| Current assets | 29/58 | €9.59M |
| Stocks & contracts in progress | 3 | €3.15M |
| Amounts receivable within one year | 40/41 | €5.22M |
| Cash & bank | 54/58 | €1.12M |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €18.19M |
| Equity | 10/15 | €4.14M |
| Contributions / capital | 10/11 | €15.24M |
| Accumulated profits (losses) | 14 | €-11.10M |
| Amounts payable | 17/49 | €14.05M |
| Amounts payable after one year | 17 | €5.52M |
| Amounts payable within one year | 42/48 | €8.49M |
| Trade debts payable within one year | 44 | €3.91M |
| Income statement | ||
| Turnover | 70 | €29.90M |
| Operating result | 9901 | €-8.55M |
| Financial income | 75 | €95 |
| Financial charges | 65 | €383k |
| Result before taxes | 9903 | €-8.94M |
| Income taxes | 67/77 | €1k |
| Net result for the period | 9904 | €-8.94M |
| Result to be appropriated | 9905 | €-8.94M |
-
Stéphane BruxAdministrateur provisoireState Gazette act 23078509 (16-06-2023)Current16-06-2023 → present
-
Jean-Paul MichielsenDirectorState Gazette act 23028206 (27-02-2023)Current27-02-2023 → present
-
Eric van der HaegenDirectorState Gazette act 22372457 (14-11-2022)Current14-11-2022 → present
-
CHAMAGADirectorState Gazette act 22372457 (14-11-2022)Current12-10-2022 → present
2 events
- 14-11-2022 Appointed· Director
- 12-10-2022 Appointed· Director
-
Michael WillemsDirectorState Gazette act 22105127 (02-09-2022)Current02-09-2022 → present
Historic, not recently confirmed (6)
-
AM CONSULTANCYDirectorState Gazette act 20054765 (05-05-2020)Not recently confirmedlast confirmed in an act from 2020
2 events
- 05-05-2020 Appointed· Director
- 28-10-2016 Appointed· Director
-
Annabelle THIRYManaging directorState Gazette act 15116920 (13-08-2015)Not recently confirmedlast confirmed in an act from 2015
-
la Compagnie du CAPDirectorState Gazette act 15116920 (13-08-2015)Not recently confirmedlast confirmed in an act from 2015
-
MFI- MARKETING FINANCE INTERNATIONALDirectorState Gazette act 15116920 (13-08-2015)Not recently confirmedlast confirmed in an act from 2015
2 events
- 05-05-2020 Resigned· Director
- 13-08-2015 Appointed· Director
-
Michaël WILLEMSPrésident du conseil d'administrationState Gazette act 15116920 (13-08-2015)Not recently confirmedlast confirmed in an act from 2015
-
Stéphane MOITYDirectorState Gazette act 15114973 (10-08-2015)Not recently confirmedlast confirmed in an act from 2015
Former directors (6)
-
Didier PêtreDirectorState Gazette act 22017588 (09-02-2022)Former09-02-2022 → 14-11-2022
3 events
- 14-11-2022 Resigned· Director
- 12-10-2022 Resigned· Director
- 09-02-2022 Appointed· Director
-
Harold LanoyDirectorState Gazette act 22372457 (14-11-2022)Former- → 14-11-2022
-
Harold LannoyDirectorState Gazette act 22017588 (09-02-2022)Former09-02-2022 → 12-10-2022
2 events
- 12-10-2022 Resigned· Director
- 09-02-2022 Appointed· Director
-
MG CONSULTINGDirectorState Gazette act 20054765 (05-05-2020)Former05-05-2020 → 09-02-2022
2 events
- 09-02-2022 Resigned· Director
- 05-05-2020 Appointed· Director
-
SAMANDA SALegal entityDirectorState Gazette act 21137724 (23-11-2021)Former- → 23-11-2021
-
THIRY Annabelle Muriel Marc MarieDirectorState Gazette act 16149767 (28-10-2016)Former- → 28-10-2016
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| Julie DelforgeCurrent Commissaire |
- | 09-02-2022 → present |
| Role | Name | Tenure | Source |
|---|---|---|---|
| Curator | ISABELLE BRONKAERT CHAUSSEE DE THUIN 164,
6032 MONT-SUR-MARCHIENNE |
19-06-2023 → present | Belgian State Gazette |
| Curator | PIERRE-EMMANUEL CORNIL RUE DE GOZEE, 137,
6110 MONTIGNY-LE-TILLEUL- .
Date provisoire de cessation de paiement : 19/06/2023 |
19-06-2023 → present | Belgian State Gazette |
| NACE primary | Overige niet-gespecialiseerde detailhandel(47120) |
| Legal form | Public limited company(014) |
| Incorporation | 27-04-2012 |
| Status | Active |
| Postal code | 7180 |
| First BS signal | 23-06-2023 |
| Latest BS signal | 23-06-2023 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 52063E0154/00D000 | Wallonia | 5.1 ha | 1 · 1,605 m² | 7.8 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
16-06-2023 Stéphane Brux appointed as administrateur provisoire
- Stéphane Brux, Administrateur provisoire
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur provisoire",
"person": {
"rrn": null,
"name": "St\u00E9phane Brux",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}08-05-2023 Capital increase of €100,000 to €25,341,764.20
- €25.241.764,20 → €25.341.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 25341764.2,
"delta_eur": 100000.0,
"before_eur": 25241764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}12-04-2023 Capital increase of €100,000 to €25,191,764.20
- €25.091.764,20 → €25.191.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 25191764.2,
"delta_eur": 100000.0,
"before_eur": 25091764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}27-03-2023 Capital increase of €150,000 to €24,941,764.20
- €24.791.764,20 → €24.941.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 24941764.2,
"delta_eur": 150000.0,
"before_eur": 24791764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}02-03-2023 Capital increase of €50,000 to €24,216,764.20
- €24.166.764,20 → €24.216.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 24216764.2,
"delta_eur": 50000.0,
"before_eur": 24166764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}27-02-2023 Jean-Paul Michielsen appointed as director
- Jean-Paul Michielsen, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Jean-Paul Michielsen",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "Pharmasimple"
}
}19-01-2023 Capital increase of €500,000 to €24,016,764.20
- €23.516.764,20 → €24.016.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 24016764.2,
"delta_eur": 500000.0,
"before_eur": 23516764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}10-01-2023 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": null,
"notary": {
"name": "Peter VAN MELKEBEKE",
"firm_city": null,
"firm_name": "Berquin Notaires",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2023-01-10",
"filing_date": "2023-01-06",
"act_kind_objet": "DIVERS"
},
"decision": {
"body": "raad_van_bestuur",
"act_date": "2022-12-27",
"unanimous": null
},
"conversion": {
"effective_date": null,
"jurisdiction_to": null,
"legal_form_after": "Soci\u00E9t\u00E9 anonyme",
"jurisdiction_from": null,
"legal_form_before": "Soci\u00E9t\u00E9 anonyme"
},
"detected_kind": "other",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0845.603.735",
"name": "PHARMASIMPLE",
"role": "other",
"address": "Boulevard Millenium(H-G) 11, 7110 La Louvi\u00E8re",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_new_company": false,
"jurisdiction_country": null
}
],
"exchange_ratio": 0.00002,
"legal_articles": [
"12:7",
"12:50"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": "1 nouvelle action pour 50.000 actions existantes",
"new_shares_issued_n": 152947,
"real_estate_included": false,
"patrimony_description": "Le regroupement concerne l\u0027ensemble du capital social de la soci\u00E9t\u00E9. Les actions existantes ont \u00E9t\u00E9 annul\u00E9es et remplac\u00E9es par un nombre r\u00E9duit d\u0027actions nouvelles, sans modification du montant du capital.",
"equity_transferred_eur": 23516764.2,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Peter VAN MELKEBEKE",
"org_rep_person_name": null
},
"summary_narrative": "Le 27 d\u00E9cembre 2022, le notaire Peter VAN MELKEBEKE a constat\u00E9 le regroupement d\u0027actions de la soci\u00E9t\u00E9 anonyme PHARMASIMPLE, r\u00E9sultant d\u0027une d\u00E9cision du conseil d\u0027administration. Ce regroupement a r\u00E9duit le nombre d\u0027actions en circulation de mani\u00E8re proportionnelle, passant de plus de 7,5 millions \u00E0 152 947 actions nouvelles, sans modification du capital social. Les anciennes actions ont \u00E9t\u00E9 annul\u00E9es. Les statuts ont \u00E9t\u00E9 modifi\u00E9s pour refl\u00E9ter cette op\u00E9ration.",
"co_filed_documents": [
"une exp\u00E9dition de l\u2019acte",
"le texte coordonn\u00E9 des statuts"
],
"detected_real_type": "other",
"referenced_correction": null,
"should_reroute_to_category": "capital_shares"
}20-12-2022 Capital increase of €75,000 to €23,516,764.20
- €23.441.764,20 → €23.516.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 23516764.2,
"delta_eur": 75000.0,
"before_eur": 23441764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}14-11-2022 2 directors appointed, 2 resigning
- Eric van der Haegen, Bestuurder
- CHAMAGA, Bestuurder
- Harold Lanoy, Bestuurder
- Didier Pêtre, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Harold Lanoy",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Didier P\u00EAtre",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Eric van der Haegen",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "CHAMAGA",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}08-11-2022 Capital increase of €150,000 to €22,841,764.20
- €22.691.764,20 → €22.841.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 22841764.2,
"delta_eur": 150000.0,
"before_eur": 22691764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}13-10-2022 Capital increase of €100,000 to €22,541,764.20
- €22.441.764,20 → €22.541.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 22541764.2,
"delta_eur": 100000.0,
"before_eur": 22441764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}12-10-2022 1 director appointed, 2 resigning
- Chamaga, Bestuurder
- Harold Lannoy, Bestuurder
- Didier Pêtre, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Harold Lannoy",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Didier P\u00EAtre",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Chamaga",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "Pharmasimple"
}
}12-09-2022 Capital increase of €200,000 to €21,791,764.20
- €21.591.764,20 → €21.791.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 21791764.2,
"delta_eur": 200000.0,
"before_eur": 21591764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}02-09-2022 Michael Willems appointed as director
- Michael Willems, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Michael Willems",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}26-08-2022 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
},
"legal_form_change": {
"new": "",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}16-08-2022 Capital increase of €150,000 to €21,241,764.20
- €21.091.764,20 → €21.241.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 21241764.2,
"delta_eur": 150000.0,
"before_eur": 21091764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}28-06-2022 Capital increase of €300,000 to €19,791,764.20
- €19.491.764,20 → €19.791.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 19791764.2,
"delta_eur": 300000.0,
"before_eur": 19491764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}03-06-2022 Capital increase of €300,000 to €18,891,764.20
- €18.591.764,20 → €18.891.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 18891764.2,
"delta_eur": 300000.0,
"before_eur": 18591764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}18-05-2022 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": null,
"notary": {
"name": "Peter VAN MELKEBEKE",
"firm_city": null,
"firm_name": "Berquin Notaires",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2022-05-18",
"filing_date": "2022-05-16",
"act_kind_objet": "DIVERS"
},
"decision": {
"body": "raad_van_bestuur",
"act_date": "2022-05-12",
"unanimous": null
},
"conversion": null,
"detected_kind": "other",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0845.603.735",
"name": "PHARMASIMPLE SA",
"role": "contributor",
"address": "Boulevard Millenium (H-G) 11, 7110 La Louvi\u00E8re",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": null
},
{
"kbo": null,
"name": "Investisseur",
"role": "recipient",
"address": null,
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": null
}
],
"exchange_ratio": null,
"legal_articles": [
"7:179",
"7:180",
"7:191",
"7:193",
"7:197"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "L\u0027apport en nature concerne des cr\u00E9ances d\u00E9tenues par l\u0027Investisseur \u00E0 l\u0027encontre de la soci\u00E9t\u00E9 Pharmasimple SA. Ces cr\u00E9ances sont transf\u00E9r\u00E9es en contrepartie de 4.000 obligations convertibles.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Peter VAN MELKEBEKE",
"org_rep_person_name": null
},
"summary_narrative": "Le conseil d\u0027administration de Pharmasimple SA a d\u00E9cid\u00E9 d\u0027\u00E9mettre 44.000 obligations convertibles d\u0027une valeur nominale de 5.000 EUR chacune, dont 40.000 en num\u00E9raire et 4.000 en apport en nature sous forme de cr\u00E9ances d\u00E9tenues par l\u0027Investisseur. Le droit de pr\u00E9f\u00E9rence des actionnaires a \u00E9t\u00E9 supprim\u00E9. L\u0027augmentation de capital interviendra conditionnellement \u00E0 la souscription et conversion des obligations. Le commissaire a confirm\u00E9 que les donn\u00E9es financi\u00E8res et l\u0027\u00E9valuation de l\u0027apport sont fid\u00E8les et suffisantes.",
"co_filed_documents": [
"proc\u00E8s-verbal",
"liste de pr\u00E9sence",
"procuration",
"rapport du conseil d\u0027administration",
"rapport du commissaire"
],
"detected_real_type": "other",
"referenced_correction": null,
"should_reroute_to_category": "capital_shares"
}28-03-2022 Capital increase of €0 to €18,491,764.20
- €18.491.764,20 → €18.491.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 18491764.2,
"delta_eur": 0.0,
"before_eur": 18491764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}10-03-2022 Capital increase of €500,000 to €16,491,764.20
- €15.991.764,20 → €16.491.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 16491764.2,
"delta_eur": 500000.0,
"before_eur": 15991764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}16-02-2022 Transaction in capital or shares
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}16-02-2022 Capital increase of €500,000 to €15,991,764.20
- €15.491.764,20 → €15.991.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 15991764.2,
"delta_eur": 500000.0,
"before_eur": 15491764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}09-02-2022 3 directors appointed, 1 resigning
- Julie Delforge, Commissaire
- Didier Pêtre, Bestuurder
- Harold Lannoy, Bestuurder
- MG Consulting, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "Julie Delforge",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "MG Consulting",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Didier P\u00EAtre",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Harold Lannoy",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}21-01-2022 Capital increase of €500,000 to €13,741,764.20
- €13.241.764,20 → €13.741.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 13741764.2,
"delta_eur": 500000.0,
"before_eur": 13241764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}08-12-2021 Capital increase of €0 to €11,991,764.20
- €11.991.764,20 → €11.991.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 11991764.2,
"delta_eur": 0.0,
"before_eur": 11991764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}23-11-2021 SAMANDA SA resigns as director
- SAMANDA SA, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "SAMANDA SA",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}22-11-2021 Capital increase of €75,000 to €8,066,764.20
- €7.991.764,20 → €8.066.764,20
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 8066764.2,
"delta_eur": 75000.0,
"before_eur": 7991764.2,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
}
}19-10-2021 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0845.603.735",
"name_full": "PHARMASIMPLE"
},
"legal_form_change": {
"new": "",
"old": "soci\u00E9t\u00E9 anonyme",
"changed": false
}
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | PHARMASIMPLE |